Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors

F. Janku, R. Abdul-Karim, A. Azad, J. Bendell, H. Gan, S. Sen, T. Tan, J. Wang, N. Marina, L. Baker, L. Ma, J. Mooney, D. Luo, J. Leveque, M. Milla, T. Meniawy

Research output: Contribution to journalMeeting AbstractOtherpeer-review

Original languageEnglish
Pages (from-to)S11
Number of pages1
JournalEuropean Journal of Cancer
Volume138
Issue numberS2
DOIs
Publication statusPublished - Oct 2020
EventEORTC/AACR/NCI International Conference on Molecular Targets and Cancer Therapeutics 2020 - Virtual Conference
Duration: 24 Oct 202025 Oct 2020
Conference number: 32nd
https://www.ejcancer.com/issue/S0959-8049(20)X0017-7

Cite this